Transgenic Animal

Advance your discovery with expert guidance on transgenic animals

Working with transgenic animals can save you the time and expense of the humanization process in your antibody discovery journey. But, just as working with other specialty animals requires experience, antibody generation from transgenic animals is benefited by hands-on experience and know-how.

Antibody Solutions has more than five years of experience working with major transgenic animal platforms such as OMT's OmniAb® platform, Harbour Antibodies™ mice, and Trianni Mouse™. We have generated therapeutic candidate human antibodies to a diverse range of challenging and novel targets. Let our experience be your advantage in antibody discovery.

An Omni Ab case study

OmniRat® and OmniMouse® Antibodies in Therapeutic Antibody Discovery

Under the Antibody Solutions and Open Monoclonal Technologies (OMT) Strategic Partnership Agreement:

Antibody Solutions can perform Services using

  • OmniRat® and OmniMouse®
  • Client obtains Research and Commercial Licenses with OMT for OmniRat® and OmniMouse® z-derived products

OmniRat and OmniMouse are the leading human antibody transgenic animal systems and allow antibody response that is superior to first-generation transgenic animals. They have normal B-cell development and normal antibody hypermutation and affinity maturation.


Antibody Solutions has optimized Ab generation with OmniRat® and OmniMouse®. Our platform includes:

  • Multiple immunization strategies (e.g., rapid, DNA, cell, etc.)

  • Hi-yield antigen-specific hybridoma generation

  • Single-cell FACs cloning (no sub-cloning required)

  • Hybridoma staining for surface IgG and antigen-binding

  • High-throughput flow screening

  • Able to produce 100's of clones in 2.5 months

Antibody Solutions is the leading CRO for monoclonal antibody discovery with both mouse and human antibodies from transgenic OmniRats. Click here to learn more about these services.


Open Monoclonal Technology, Inc.

Results for 12 Therapeutic Targets


Hybridoma clones have been generated and selected to 12 human therapeutic targets including five (5) targets with >85% AA sequence identities to the rat homologue. Up to several hundred clones have been obtained in a single cloning step for each target. (Poster Link Ab Summary)

Antibody Diversity / V-Gene Usage


Sequencing of the antibody genes used by four sets of positive clones showed good diversity against conserved target antigens. Almost all of the functional germ lone gene families present in OmniRat® were found in target-specific antibody-secreting clones.

Standard Abs

Transgenic standard abs


Fixed L Chain Abs

Transgenic fixed L Chain



Transgenic nanobodies